Current treatment strategies for measurable residual disease in patients with acute myeloid leukemia

被引：13

作者：

Percival, Mary-Elizabeth M. ^{[1
,2
]}

Estey, Elihu H. ^{[1
,2
]}

机构：

[1] Univ Washington, Dept Med, Div Hematol, 825 Eastlake Ave E,MS CE3-300, Seattle, WA 98109 USA

[2] Fred Hutchinson Canc Res Ctr, Div Clin Res, 1124 Columbia St, Seattle, WA 98104 USA

来源：

CANCER | 2019年 / 125卷 / 18期

关键词：

acute myeloid leukemia (AML); clinical trials; complete remission; measurable residual disease (MRD); HEMATOPOIETIC-CELL TRANSPLANTATION; COMPLETE REMISSION; PROGNOSTIC IMPACT; GEMTUZUMAB OZOGAMICIN; RISK STRATIFICATION; DIRECTED THERAPY; IMPROVE OUTCOMES; FLOW-CYTOMETRY; AML; RELAPSE;

D O I：

10.1002/cncr.32354

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Patients with acute myeloid leukemia (AML) who achieve a morphologic complete remission still can have measurable residual disease (MRD) detected by multiparametric flow cytometry, molecular methods, or cytogenetics. Such patients with MRD have a high risk of disease recurrence over a short timeframe, but optimal treatment strategies are unknown. Outcomes with conventional treatment, including allogeneic hematopoietic cell transplantation, are worse than those for patients without MRD. Herein, the authors review current strategies, including novel clinical trials, targeted toward patients with MRD.

引用

页码：3121 / 3130

页数：10

共 49 条

[41]

Versluis J, 2017, HAEMATOLOGICA, V102, P7

[42] Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation [J].

Walter, R. B. ;

Gyurkocza, B. ;

Storer, B. E. ;

Godwin, C. D. ;

Pagel, J. M. ;

Buckley, S. A. ;

Sorror, M. L. ;

Wood, B. L. ;

Storb, R. ;

Appelbaum, F. R. ;

Sandmaier, B. M. .

LEUKEMIA, 2015, 29 (01) :137-144

[43] Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission [J].

Walter, Roland B. ;

Buckley, Sarah A. ;

Pagel, John M. ;

Wood, Brent L. ;

Storer, Barry E. ;

Sandmaier, Brenda M. ;

Fang, Min ;

Gyurkocza, Boglarka ;

Delaney, Colleen ;

Radich, Jerald P. ;

Estey, Elihu H. ;

Appelbaum, Frederick R. .

BLOOD, 2013, 122 (10) :1813-1821

[44] Impact of Pretransplantation Minimal Residual Disease, As Detected by Multiparametric Flow Cytometry, on Outcome of Myeloablative Hematopoietic Cell Transplantation for Acute Myeloid Leukemia [J].

Walter, Roland B. ;

Gooley, Ted A. ;

Wood, Brent L. ;

Milano, Filippo ;

Fang, Min ;

Sorror, Mohamed L. ;

Estey, Elihu H. ;

Salter, Alexander I. ;

Lansverk, Emily ;

Chien, Jason W. ;

Gopal, Ajay K. ;

Appelbaum, Frederick R. ;

Pagel, John M. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (09) :1190-1197

[45] The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia [J].

Williams, Patrick ;

Basu, Sreyashi ;

Garcia-Manero, Guillermo ;

Hourigan, Christopher S. ;

Oetjen, Karolyn A. ;

Cortes, Jorge E. ;

Ravandi, Farhad ;

Jabbour, Elias J. ;

Al-Hamal, Zainab ;

Konopleva, Marina ;

Ning, Jing ;

Xiao, Lianchun ;

Lopez, Juliana Hidalgo ;

Kornblau, Steve M. ;

Andreeff, Michael ;

Flores, Wilmer ;

Bueso-Ramos, Carlos ;

Blando, Jorge ;

Galera, Pallavi ;

Calvo, Katherine R. ;

Al-Atrash, Gheath ;

Allison, James P. ;

Kantarjian, Hagop M. ;

Sharma, Padmanee ;

Daver, Naval G. .

CANCER, 2019, 125 (09) :1470-1481

[46] Factors Determining Responses to Azacitidine in Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia with Early Post-Transplantation Relapse: A Prospective Trial [J].

Woo, Janghee ;

Deeg, H. Joachim ;

Storer, Barry ;

Yeung, Cecilia ;

Fang, Min ;

Mielcarek, Marco ;

Scott, Bart L. .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2017, 23 (01) :176-179

[47] Prophylactic Donor Lymphocyte Infusion (DLI) Followed by Minimal Residual Disease and Graft-versus-Host Disease-Guided Multiple DLIs Could Improve Outcomes after Allogeneic Hematopoietic Stern Cell Transplantation in Patients with Refractory/Relapsed Acute Leukemia [J].

Yan, Chen-Hua ;

Liu, Qi-fa ;

Wu, De-pei ;

Zhang, Xi ;

Xu, Lan-Ping ;

Zhang, Xiao-hui ;

Wang, Yu ;

Huang, He ;

Bai, Hai ;

Huang, Fen ;

Ma, Xiao ;

Huang, Xiao-Jun .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2017, 23 (08) :1311-1319

[48] Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial [J].

Yin, John A. Liu ;

O'Brien, Michelle A. ;

Hills, Robert K. ;

Daly, Sarah B. ;

Wheatley, Keith ;

Burnett, Alan K. .

BLOOD, 2012, 120 (14) :2826-2835

[49] MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial [J].

Zhu, Hong-Hu ;

Zhang, Xiao-Hui ;

Qin, Ya-Zhen ;

Liu, Dai-Hong ;

Jiang, Hao ;

Chen, Huan ;

Jiang, Qian ;

Xu, Lan-Ping ;

Lu, Jin ;

Han, Wei ;

Bao, Li ;

Wang, Yu ;

Chen, Yu-Hong ;

Wang, Jing-Zhi ;

Wang, Feng-Rong ;

Lai, Yue-Yun ;

Chai, Jun-Yue ;

Wang, Li-Ru ;

Liu, Yan-Rong ;

Liu, Kai-Yan ;

Jiang, Bin ;

Huang, Xiao-Jun .

BLOOD, 2013, 121 (20) :4056-4062

← 1 2 3 4 5 →